Vise Technologies Inc. Raises Stock Holdings in Pfizer Inc. $PFE

Vise Technologies Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 44.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 314,153 shares of the biopharmaceutical company’s stock after buying an additional 96,548 shares during the quarter. Vise Technologies Inc.’s holdings in Pfizer were worth $7,565,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in PFE. Norges Bank purchased a new stake in Pfizer in the 4th quarter worth approximately $1,830,986,000. BlackRock Inc. lifted its holdings in Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares in the last quarter. Morgan Stanley boosted its position in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Pfizer by 38.9% in the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Finally, Janus Henderson Group PLC increased its stake in shares of Pfizer by 577.5% in the fourth quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after purchasing an additional 7,489,189 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Weiss Ratings downgraded shares of Pfizer from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, August 17th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a report on Tuesday, June 9th. UBS Group reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a report on Wednesday, May 27th. Cantor Fitzgerald restated a “neutral” rating and issued a $27.00 price objective on shares of Pfizer in a research report on Monday, July 6th. Finally, Bank of America dropped their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.28.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer completed a Phase 1/2 study of PF-07868489, an experimental treatment for pulmonary arterial hypertension. The milestone supports early-stage pipeline progress, though additional clinical testing will be needed before any potential commercialization. Pfizer’s PF-07868489 PAH Study Reaches Completion
• Positive Sentiment: Several additional clinical updates highlighted progress across Pfizer’s development portfolio: completion of a Phase 1 atirmociclib study, completion of a drug-interaction study for PF-07248144, and a new Phase 1 liver study for atirmociclib. These milestones may reinforce confidence in Pfizer’s ability to replenish revenue as older products face competition. Atirmociclib Study Update PF-07248144 Study Update
• Positive Sentiment: Pfizer is also expanding real-world evidence efforts for prostate cancer therapies, Ibrance in advanced breast cancer, and a migraine treatment study in India. These studies could support broader use and strengthen commercial evidence for existing medicines. Pfizer Real-World Prostate Cancer Study
• Positive Sentiment: Investor-oriented coverage remains constructive, citing Pfizer’s roughly 19% year-to-date gain, attractive dividend yield, and reported hedge-fund buying. The stock’s move toward its 52-week high suggests improving sentiment. Hedge Funds Buying Pfizer
• Neutral Sentiment: Unusually large options activity may increase short-term trading interest, but it does not establish a clear fundamental direction for PFE. Pfizer Options Trading
• Negative Sentiment: Coverage of settlements involving thousands of Depo-Provera lawsuits raises concerns about potential legal costs and ongoing liability. Analysts also continue to weigh whether new drugs and acquisitions can offset revenue losses from expiring patents. Pfizer Legal Claims

Pfizer Price Performance

Shares of NYSE:PFE opened at $28.00 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. The firm has a fifty day moving average price of $25.30 and a 200 day moving average price of $26.25. Pfizer Inc. has a fifty-two week low of $23.58 and a fifty-two week high of $28.75. The firm has a market cap of $159.59 billion, a price-to-earnings ratio of 36.84 and a beta of 0.34.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. Pfizer’s revenue for the quarter was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.78 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.1%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.